Victory Capital Management Inc. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 502,960 shares of the medical device company’s stock after purchasing an additional 8,657 shares during the quarter. Victory Capital Management Inc. owned approximately 0.57% of DexCom worth $71,944,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Waddell & Reed Financial Inc. raised its holdings in shares of DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after purchasing an additional 354,331 shares during the period. UBS Group AG raised its holdings in shares of DexCom by 76.3% in the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after purchasing an additional 6,890 shares during the period. BlackRock Inc. raised its holdings in shares of DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after purchasing an additional 228,933 shares during the period. Macquarie Group Ltd. raised its holdings in shares of DexCom by 14.4% in the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after purchasing an additional 29,825 shares during the period. Finally, Federated Investors Inc. PA raised its holdings in DexCom by 97.1% in the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock valued at $43,710,000 after acquiring an additional 226,740 shares during the period.
In other news, CEO Kevin R. Sayer sold 11,161 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $123.22, for a total transaction of $1,375,258.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, October 10th. The stock was sold at an average price of $122.20, for a total transaction of $48,880.00. The disclosure for this sale can be found here. Insiders have sold 170,392 shares of company stock worth $23,416,280 over the last ninety days. Insiders own 1.80% of the company’s stock.
Several research analysts have weighed in on the stock. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Canaccord Genuity increased their price target on shares of DexCom from $125.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, August 23rd. Stephens increased their price target on shares of DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, August 23rd. Robert W. Baird increased their price target on shares of DexCom from $140.00 to $160.00 and gave the company a “positive” rating in a report on Thursday, August 23rd. Finally, BidaskClub cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 18th. Eight equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. DexCom has a consensus rating of “Buy” and a consensus target price of $129.06.
Shares of DXCM opened at $130.84 on Tuesday. DexCom, Inc. has a 12 month low of $48.90 and a 12 month high of $148.56. The company has a market cap of $11.72 billion, a PE ratio of -225.59 and a beta of 0.60. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69.
TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Bought by Victory Capital Management Inc.” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/06/dexcom-inc-dxcm-shares-bought-by-victory-capital-management-inc.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.